Zhao Lujun, Chen Ming, Ten Haken Randall, Chetty Indrin, Chapet Olivier, Hayman James A, Kong Feng-Ming
Department of Radiation Oncology, University of Michigan Health System, Ann Arbor, MI 48109, USA.
Radiother Oncol. 2007 Feb;82(2):153-9. doi: 10.1016/j.radonc.2007.01.006. Epub 2007 Feb 6.
To determine the dose to regional nodal stations in patients with T1-3N0M0 non-small cell lung cancer (NSCLC) treated with three-dimensional conformal radiation therapy (3DCRT) without intentional elective nodal irradiation (ENI).
Twenty-three patients with medically inoperable T1-3N0M0 NSCLC were treated with 3DCRT without ENI. Hilar and mediastinal nodal regions were contoured on planning CT. The prescription dose was normalized to 70 Gy. Equivalent uniform dose (EUD) and other dosimetric parameters (e.g., V40) were calculated for each nodal station.
The median EUD for the whole group ranged from 0.4 to 4.4 Gy for all elective nodal regions. Gross tumor volume (GTV) and the relationship between GTV and hilum were significantly correlated with irradiation dose to ipsilateral hilar nodal regions (P<.05). For patients with GTV>or=30.2 cm3 (diameter approximately 4 cm) and or having any overlap with hilum, the median EUDs were 9.6, 22.6, and 62.9 Gy for ipsilateral lower paratracheal, subcarinal, and ipsilateral hilar regions, respectively. The corresponding median V40 were 32.5%, 39.3%, and 97.6%, respectively.
Although incidental nodal irradiation dose is low in the whole group, the dose to high-risk nodal regions is considerable in patients with T1-3N0 NSCLC when the primary is large and/or centrally located.
确定T1 - 3N0M0期非小细胞肺癌(NSCLC)患者在接受三维适形放疗(3DCRT)且未进行选择性淋巴结预防照射(ENI)时区域淋巴结站的剂量。
23例医学上无法手术的T1 - 3N0M0期NSCLC患者接受了无ENI的3DCRT治疗。在计划CT上勾勒出肺门和纵隔淋巴结区域。处方剂量归一化为70 Gy。计算每个淋巴结站的等效均匀剂量(EUD)和其他剂量学参数(如V40)。
全组所有选择性淋巴结区域的EUD中位数范围为0.4至4.4 Gy。原发肿瘤体积(GTV)以及GTV与肺门的关系与同侧肺门淋巴结区域的照射剂量显著相关(P<0.05)。对于GTV≥30.2 cm³(直径约为4 cm)或与肺门有任何重叠的患者,同侧气管旁下、隆突下和同侧肺门区域的EUD中位数分别为9.6、22.6和62.9 Gy。相应的V40中位数分别为32.5%、39.3%和97.6%。
虽然全组患者的偶然淋巴结照射剂量较低,但对于T1 - 3N0期NSCLC患者,当原发肿瘤较大和/或位于中央时,高危淋巴结区域的剂量相当可观。